Endomag: New procedure spares women with breast cancer from unnecessary surgical complication
Targeted Axillary Dissection (TAD) is a new surgical technique that allows surgeons to assess cancer in specific lymph nodes while minimising the patient’s risk of developing lymphedema linked to their treatment.
![330 Cambridge Science Park [copyright – Bidwells]](/sites/default/files/styles/article_card/public/330%20Cambridge%20Science%20Park.jpg?itok=cuWs6Gno)
Endomag secures Cambridge Science Park space for new UK headquarters
Endomag, a breast cancer surgical guidance company and one of the UK’s fastest-growing private technology businesses, has secured 20,386 sq ft of space at 330 Cambridge Science Park. Advised by Carter Jonas, Endomag has agreed a ten-year lease at the world-renowned Science Park location.
NICE issues a positive medtech innovation briefing for Endomag’s Magtrace® breast cancer lymphatic tracer
Endomag’s lymphatic tracer, Magtrace®, has received a positive Medtech Innovation Briefing (MIB) from the National Institute for Health and Care Excellence (NICE) for locating sentinel lymph nodes.
Endomag wins second Queen’s Award for Enterprise
Endomag has been officially honoured with a 2021 Queen’s Award for Enterprise in International Trade.
Endomag named one of Europe’s fastest growing companies by the Financial Times
Endomag has been officially named as one of the ‘FT 1000: Europe’s Fastest Growing Companies of 2021’, as published in a recent edition of the Financial Times newspaper. Three other Cambridge Network member companies also feature in the list.
Endomag secures £15 million ($20 million) in Series D funding
Endomag, a breast cancer market leader and one of the UK’s fastest growing private technology businesses1, has secured £15m (~$20m) in Series D funding. These funds are earmarked for expanding access to new advanced techniques enabled by its products, such as targeted axillary dissection (TAD) and delayed sentinel lymph node biopsy (dSLNB). The funds will also be used to scale its product…
Endomag CEO features in Telegraph article about Brexit transition
Eric Mayes, CEO of Cambridge-based Endomag, tells The Telegraph that thorough preparation has made his firm future-proof, as businesses across the UK prepare for the end of the Brexit transition period on 31 December.
Endomag technology shortlisted for ‘Best Medical Technology’ award
Technology for breast cancer care from Cambridge-based Endomag has been recognised by an international award programme.
Endomag steps up to support NHS
In partnership with Sysmex Europe, Cambridge based Endomag is supporting the NHS by donating free Magtrace® lymphatic tracer vials to UK hospitals, to help continue carrying out essential breast cancer treatment during the Covid-19 outbreak.
European breast cancer patients can now access more convenient and targeted treatment with new Magseed® marker indication
Endomag, the market leader for seed localisation in Europe, has received an extended indication for the long-term use of its Magseed® magnetic marker in any soft tissue.
Endomag wins ‘International Expansion of the Year’ award at Barclays’ High Growth and Entrepreneurs Awards ceremony
Endomag, based at St John’s Innovation Park, Cambridge, has won the ‘International Expansion of the Year’ award at the Barclays’ annual High Growth and Entrepreneur Awards. The awards were announced by Sir Trevor McDonald at the Bloomsbury Ballroom in central London.
Endomag surgical guidance system wins Institute of Physics’ Business Innovation Award
Endomag, the surgical guidance company, has won a prestigious British Business Innovation Award from the Institute of Physics (IOP), presented at the Houses of Parliament in London.
Breast cancer device receives FDA approval
Endomag, the surgical guidance company, announced that it has received premarket approval (PMA) from the US Food and Drug Administration (FDA) for Magtrace, the first non-radioactive, dual-tracer for lymphatic mapping in patients with breast cancer undergoing a mastectomy.
Endomag raises $10 million USD (£8M GBP) to establish a new standard of breast cancer care
Surgical guidance company, Endomagnetics Ltd (Endomag), today announced that it has raised $10 million USD (£8M GBP) Series C funding, led by Draper Esprit. This investment brings total funding for Endomag to over $22 million USD (£17m GBP) and will enable the company to significantly expand its capabilities, with the aim of treating more cancer patients around the world.
British breast cancer company, Endomag, wins Queen’s Award
Endomag, the surgical guidance company, today announced it has received the Queen’s Award for Enterprise in Innovation for 2018. The Award recognises the Company’s efforts in developing novel surgical tools for more accurate removal of breast cancer.
University Hospitals system adopts Magseed marker as standard of care
Endomag, the surgical guidance company, announced that University Hospitals (UH), one of the leading healthcare systems in the US, providing high-quality, patient-centred cancer care at locations throughout Northeast Ohio, has expanded the use of its Magseed® marker technology at more sites within the UH system.
Endomag’s Magseed marker receives FDA clearance for long-term and soft tissue implantation
Endomag, the surgical guidance company, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to extend the indication of its Magseed® magnetic marker to include both the marking of soft tissue and long-term implantation.
Endomag receives CE Mark approval for Magseed breast cancer localisation technology
Endomag, the surgical guidance company, announced that it has received CE Mark approval for Magseed®, a minimally invasive breast marker used to accurately guide surgeons during breast cancer removal.
Endomag strengthens Board with key appointment
Endomag, the cancer healthcare company, has announced the appointment of Peter Keen as non-executive director, effective immediately.
UCSF first to adopt Magseed as standard of care for localization of impalpable breast lesions
Endomag, the cancer healthcare company, announced that the University of California, San Francisco (UCSF) has become the first US site to adopt Magseed™ as its standard of care for localization of impalpable breast lesions. Magseed™ is a simpler, more effective alternative to traditional wire localization methods.
Endomag’s system demonstrated non-inferior to standard of care for sentinel node detection
Multi-centre trial indicates potential for Endomag’s system to be used as a non-radioactive alternative for sentinel lymph node detection in early stage breast cancer.
Endomag’s breast tumor localization system granted FDA 510(k) clearance
Endomag, the cancer healthcare company, announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Magseed® magnetic marker for use with Sentimag®.